Nutrition Tracking and Continuous Glucose Monitors for People Without Diabetes

Quick answer

Food logging has research support in weight-loss programs, though the evidence has limits and it does not suit everyone. Continuous glucose monitors (CGMs) are small skin sensors that read glucose in fluid under the skin. They are proven tools for people with diabetes who use insulin; for people without diabetes, benefits are unproven. Labels used: established, promising but limited, insufficient evidence, marketing claim.

Nutrition Tracking

What research shows. A systematic review of self-monitoring in weight-loss programs found a consistent link between tracking and weight loss, but called the evidence weak because of methodology limits and reliance on self-report. [1] A later review of digital self-monitoring in 39 trials found greater tracking was linked to weight loss in 74% of occurrences. [2] Label: promising but limited; these are mostly studies of adults in structured weight-loss programs, so we do not know how well it applies to other goals.

When it can backfire. A 2025 survey of 386 Australian women aged 17 to 35 found users of diet-monitoring apps had more disordered eating, body dissatisfaction and compulsive exercise than non-users. [3] This shows a link, not that apps cause it. If you have a history of an eating disorder or find counting stressful, skip tracking and ask a clinician. See also prediabetes and metabolic syndrome.

Continuous Glucose Monitors for People Without Diabetes

Regulatory status. The FDA cleared the first over-the-counter CGM for adults 18 and older who do not use insulin, including people without diabetes who want to understand how diet and exercise may affect blood sugar. [4] It is not for people with problematic hypoglycemia (dangerously low blood sugar), because it is not designed to alert the user to it, and users should not make medical decisions from its output without talking with a provider. [4] This is a US statement; rules differ elsewhere and change.

What the evidence shows. A 2026 review in JAMA Internal Medicine found randomized trials in type 2 diabetes show a modest average A1c reduction of about 0.3%, but only limited and indirect evidence supports CGM in people with type 2 diabetes not on glucose-lowering treatment, prediabetes or obesity. [5] The review said CGM should answer a specific patient problem rather than be a default tool, and warned against overuse where benefit is unproven. [5] A separate systematic review on healthy people without diabetes noted that data are scarce and the effect on cardiovascular outcomes is unclear. [6] Label: insufficient evidence of health benefit.

Reading the numbers. Glucose normally rises and falls with meals and activity. We did not find a source we could read that defines a "normal" range or response for healthy people, so we do not give targets: Proper evidence not found (we checked FDA, PubMed). Ask a clinician if readings worry you.

Watches and rings. Devices that claim to read glucose without a sensor under the skin are not cleared; see wearables. [7]

Stop signs and when to see a clinician

Talk with a clinician before acting on glucose data; see talking with a health professional. For claim-checking tips see how to evaluate a biohack.

Any symptom that worries you, such as fainting or confusion, needs medical care, not an app. In a US emergency call 911.